Autism Treatment Market Size, Share, Growth, Trends, and Global Industry Analysis: By Autism Type (Autistic Disorder, Asperger Syndrome, Pervasive Developmental Disorder, Childhood Disintegrative Disorder); By Treatment Approach (Behavioural Approaches, Early Intervention, Medication, Dietary Approach) By Drug (Risperidone, Aripiprazole, Clozapine, Haloperidol, Sertraline, Methylphenidate, Venlafaxine, Fluoxetine, Others), By Region Forecast 2020-2031

Autism Treatment Market size was valued at US$ 30,928.8 million in 2024 and is expected to reach US$ 47,123.2 million by 2031, growing at a significant CAGR of 6.20%
from 2025-2031. The global market provides a detailed overview that can be segmented by autism type, by treatment approach, and by drug. By autism type, the global market has been segmented into Autistic Disorder, Asperger Syndrome, Pervasive Developmental Disorder, and Childhood Disintegrative Disorder. The Autistic Disorder segment is likely to be the largest and fastest-growing segment in terms of type in 2021 due to the high prevalence of this disease. Based on treatment approach, the market is segmented into Behavioural Approaches, Early Intervention, Medication, and Dietary Approaches. Among these, the Behavioural Approaches segment is expected to have the fastest-growing market during the forecast period. 

According to precision business insights. Based on the drug, the global market is segmented into Risperidone, Aripiprazole, Clozapine, Haloperidol, Sertraline, Methylphenidate, Venlafaxine, Fluoxetine, and Others. The Risperidone segment accounts for the largest share in 2021 and is expected to maintain the trend in the upcoming years. It is attributed to increased focus and decreased hyperactivity in the patient. Autism spectrum disorders, or pervasive developmental disorders (PDDs), are neurodevelopmental disorders which a subjective disability in a social association, debilitated correspondence, and stereotyped examples of conduct. The most well-known types of PDD are autistic issues, Asperger's issues, and unavoidable formative issues not generally indicated (PDD NOS). The increased prevalence of autism is anticipated to create demand for the market.

Key Development

• In Oct 2022, AXA Health launched neurodiversity services for group PMI In May 2022, Group launched mobile application for Autism therapy in Nigeria.